ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1340

To Study Real-World Effectiveness of Paclitaxel Drug-Coated Balloon Angioplasty in Hemodialysis Patients

Session Information

  • Vascular Access
    October 22, 2020 | Location: On-Demand
    Abstract Time: 10:00 AM - 12:00 PM

Category: Dialysis

  • 704 Dialysis: Vascular Access

Authors

  • Oo, Pye, University of Wisconsin-Madison, Madison, Wisconsin, United States
  • Alagusundaramoorthy, Sayee Sundar, University of Wisconsin-Madison, Madison, Wisconsin, United States
  • Karim, Muhammad Sohaib, University of Wisconsin-Madison, Madison, Wisconsin, United States
  • Chan, Micah R., University of Wisconsin-Madison, Madison, Wisconsin, United States
  • Astor, Brad C., University of Wisconsin-Madison, Madison, Wisconsin, United States
  • Gardezi, Ali I., University of Wisconsin-Madison, Madison, Wisconsin, United States
Background

A large, multicenter randomized study has shown that use of drug coated balloon (DCB) in angioplasty improves vascular access patency trend over control at 9-month during 2-year study period. We have conducted a retrospective study to see if there is a real-world effectiveness of DCB angioplasty in maintaining vascular access patency in hemodialysis patients.

Methods

We retrospectively reviewed 83 drug coated balloon angioplasties performed in our hospital from April 2018 to April 2020 and compared them with a control group of 83 angioplasties done by non-drug coated balloon matched by the date of procedure. Target lesions were categorized as central, peripheral, anastomotic and in-stent for both arteriovenous fistulae (AVF) and arteriovenous grafts (AVG). Patient demographics (Age, Sex) and risk factors (Hypertension, Hyperlipidemia, Vascular Disease, Diabetes Mellitus) were also compared. The duration of target lesion patency (in days) before and after the DCB interventions were compared with date matched non-DCB interventions (control group).

Results

There are 83 angioplasties in each group (DCB versus control group). The average duration of target lesion patency (in days) before intervention in DCB and control group were 152 versus 137 (P value = 0.57) for AVF and 163.3 versus 191.3 (P value = 0.70) for AVG respectively. The average duration of target lesion patency (in days) after intervention in DCB group and control group were 114.8 versus 161.7 (P value = 0.03) for AVF and 177.9 versus 221.5 (P value = 0.5) for AVG respectively.

Conclusion

As opposed to the randomized controlled trial, our study shows that the average duration of target lesion patency of AVF after drug coated balloon angioplasty was significantly shorter than non-drug coated balloon. Greater severity of lesions in the DCB group could be the reason for this observation.

Target Lesion Patency Outcomes
Type of AccessDuration of Patency
(Days)
Drug Coated Balloon
N=83
Non Drug Coated Balloon
N=83
P-Value
AVFPre-intervention152.5137.90.57
Post-intervention114.8161.70.03
AVGPre-intervention163.3191.30.70
Post-intervention177.9221.50.50